Stable expression of Epstein-Barr virus BZLF-1-encoded ZEBRA protein activates p53-dependent transcription in human Jurkat T-lymphoblastoid cells

Blood

Volumn 96, Issue 2, 2000, Pages 625-634

  Dreyfus, David H ^a   Nagasawa, Masayuki ^a   Kelleher, Colm A ^a   Gelfand, Erwin W ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMEDIATE EARLY PROTEIN BZLF1; PROTEIN P53; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TRANSACTIVATION;

EID: 0034661828     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.2.625.014k27_625_634     Document Type: Article

References (61)

1. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev. 1996;10:1054.
2. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323.
3. Hawley RS, Friend SH. Strange bedfellows in even stranger places: the role of ATM in meiotic cells, lymphocytes, tumors, and its functional links to p53. Genes Dev. 1996;10:2383.
4. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet. 1992;1:45.
5. Kern SE, Pietenpol JA, Thiagalingam S, Seymor A, Kinzler KW, Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science. 1992;256:827.
6. Pietenpol JA, Tokino T, Thiagalingam S, el-Deiry WS, Kinzler KW, Vogelstein B. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci U S A. 1994;91:1998.
7. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817.
8. Macleod KF, Sherry N, Hannon G, et al. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 1995;9:935,
9. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 1997;91:325.
10. Hupp TR, Sparks A, Lane DP. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell. 1995;83:237.
11. Shiloh Y. Ataxia-telangectasia and the nijmegen breakage syndrome: related disorders but genes apart. Annu Rev Genet. 1997;31:635.
12. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 1993; 329:1318.
13. Teodoro JG, Branton PE. Regulation of apoptosis by viral gene products. J Virol. 1997;71:1739.
14. Kieff E, Shenk T. Modulation of apoptosis by herpes viruses. Semin Virol. 1998;8:471.
15. Sarnow P, Ho YS, Williams J, Levine AJ. Adenovirus E1b-58 kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell. 1982;23:387.
16. Martin MED, Berk AJ. Adenovirus E1B 55K represses p53 activation in vitro. J Virol. 1998;72: 3146.
17. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990;248:76.
18. Jones DL, Thompson DA, Munger K. Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis. Virology. 1997;239:97.
19. Daniels PR, Sanders CM, Maitland NJ. Characterization of the interactions of human papilloma-virus type 16 E6 with p53 and E6-associated protein in insect and human cells. J Gen Virol. 1998; 79:489.
20. Pise-Masison CA, Choi KS, Radonovich M, Dittmer J, Kim SJ, Brady JN. Inhibition of p53 transactivation function by the human T-cell lymphotropic virus type 1 tax protein. J Virol. 1998;72: 1165.
21. Duan L, Ozaki I, Oakes JW, Taylor JP, Khalili K, Pomeranz RJ. The tumor suppressor p53 strongly alters human immunodeficiency virus type 1 replication. J Virol. 1994;68:4302.
22. Subler MA, Martin DW, Deb S. Activation of the human immunodeficiency virus type 1 long terminal repeat by transforming mutants of human p53. J Virol. 1994;68:103.
23. Greenway A, Azad A, McPhee D. Human immunodeficiency virus type 1 Nef protein inhibits activation pathways in peripheral blood mononuclear cells and T-cell lines. J Virol. 1995;69:1842.
24. Li CJ, Wang C, Friedman DJ, Pardee AB. Reciprocal modulations between p53 and Tat of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 1995;92:5461.
25. Longo F, Marchetti MA, Castagnolli L, Battaglia PA, Gigliani F. A novel approach to protein-protein interaction: complex formation between the p53 tumor suppressor and the HIV TAT proteins. Biochem Biophys Res Comm. 1995;206:326.
26. Fortunato EA, Spector DH. p53 and RPA are sequestered in viral replication centers in the nuclei of cells infected with human cytomegalovirus. J Virol. 1998;72:2033.
27. Kashanchi F, Araujo J, Doniger J, et al. Human herpes virus 6 (HHV-6) ORF-1 transactivating gene exhibits malignant transforming activity and its protein binds to p53. Oncogene. 1997;14:359.
28. Zhang O, Gutsch D, Kenney S. Functional and physical interaction between p53 and BZLF-1: implications for Epstein-Barr virus latency. Mol Cell Biol. 1994;14:1929.
29. Cayrol C, Flemington EK. The Epstein-Barr virus bZIP transcription factor Zta causes G0/G1 cell cycle arrest through induction of cyclin dependent kinase inhibitors. EMBO J. 1996;15:2748.
30. Chen W, Cooper NR. Epstein-Barr virus nuclear antigen 2 and latent membrane protein independently transactivate p53 through induction of NF-kB activity. J Virol. 1996;70:4849.
31. Farrell PJ, Allan GJ, Shanahan F, Vousdan KH, Crook T. p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J. 1991;10:2879.
32. Countryman J, Jenson H, Seibl R, Wolf H, Miller G. Polymorphic proteins encoded within BZLF-1 of defective and standard Epstein-Barr viruses disrupt latency. J Virol. 1987;61:3672.
33. Farrell PJ, Rowe DT, Rooney CM, Kouzarides T. Epstein-Barr virus BZLF-1 trans-activator specifically binds to a consensus AP-1 site and is related to c-fos. EMBO J. 1989;8:127.
34. Flemington E, Speck SH. Epstein-Barr virus BZLF1 trans-activator induces the promoter of a cellular cognate gene, c-fos. J Virol. 1990;64:4549.
35. Gutsch DE, Holley-Guthrie EA, Zhang Q, et al. The bZIP transactivator of Epstein-Barr virus, BZLF-1, functionally and physically interacts with the p65 subunit of NF-κB. Mol Cell Biol. 1994;14: 1939.
36. Sista ND, Barry C, Sampson K, Pagano JS. Physical and functional interaction of the Epstein-Barr virus BZLF1 transactivator with the retinoic acid receptors RARa and RXRa. Nucl Acids Res. 1995;23:1729.
37. Lieberman PM, Berk AJ. The Zta trans-activator protein stabilizes TFIID association with promoter DNA by direct protein-protein interaction. Genes Dev. 1991;5:2441.
38. Kouzarides T, Packham C, Cook A, Farrell PJ. The BZLF-1 protein of EBV has a coiled coil dimerisation domain without a heptad leucine repeat but with homology to the C/EBP leucine zipper. Oncogene. 1991;6:195.
39. Terada N, Lucas JJ, Gelfand EW. Differential regulation of the tumor suppressor molecules, retinoblastoma susceptibility gene product (Rb) and p53, during cell cycle progression of normal human T cells. J Immunol. 1991;147: 698.
40. Jones JF, Shurin S, Abramowsky C, et al. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. N Engl J Med. 1988;318:733.
41. Chen C, Sadler RH, Walling DM, Su I, Hsieh H, Raab-Traub N. Epstein-Barr virus (EBV) gene expression in EBV-positive peripheral T-cell lymphomas J Virol. 1993;67:6303.
42. Kanegane H, Bhatia K, Gutierrez M, et al. A syndrome of peripheral blood T-cell infection with Epstein-Barr virus (EBV) followed by EBV-positive T-cell lymphoma. Blood. 1998;91: 2085.
43. Kelleher CA, Kaufman-Patterson R, Dreyfus DH, et al. Epstein-Barr virus replicative gene transcription during de novo infection of human thymocytes: simultaneous early expression of BZLF-1 and its represser RAZ. Virology. 1995; 208:685.
44. Dreyfus DH, Kelleher CA, Jones JF, Gelfand EW. Epstein-Barr virus infection of T cells: implications for altered T-lymphocyte activation, repertoire development, and autoimmunity. Immunol Rev. 1996;152:89.
45. Guan M, Zhang RD, Wu B, Henderson EE. Infection of primary CD4+ and CD8+ T lymphocytes by Epstein-Barr virus enhances human immunodeficiency virus expression. J Virol. 1996;70:7341.
46. Katz BZ, Berkman AB, Shapiro ED. Serologicevidence of active Epstein-Barr virus infection in Epstein-Barr virus-associated lymphoproliferative disorders of children with acquired immunodeficiency syndrome. J Pediatr. 1992;120:228.
47. Sinha SK, Todd SC, Hedrick JA, Speiser CL, Lambris JD, Tsoukas CD. Characterization of the EBV/C3d receptor on the human Jurkat T cell line. J Immunol. 1993;150:5311.
48. Li X, Coffino P. Identification of a region of p53 that confers lability. J Biol Chem. 1996;271:4447.
49. Ciechanover A, Shkedy D, Oren M, Bercovich B. Degradation of the tumor suppressor protein p53 by the ubiquitin-mediated proteolytic system requires a novel species of ubiquitin-carrier protein E2. J Biol Chem. 1994;269:9582.
50. Rickinson AB, Kieff E. Epstein-Barr virus. Fields Virology. Philadelphia: Lippincott-Raven; 1996: 2397-2446.
51. Schreiber E, Matthias P, Muller MM, Schaffner W. Rapid detection of octamer binding proteins with "mini-extracts" prepared from a small number of cells. Nucl Acids Res. 1989;17:6419.
52. Monks CR, Kupfer H, Tamir I, Barlow A, Kupfer A. Selective modulation of protein kinase C during T-cell activation. Nature. 1997;385:83.
53. Daibata M, Humphreys RE, Sairenji T. Phosphorylation of the Epstein-Barr virus immediate-early gene product BZLF-1. Virology. 1992;188:916.
54. Dreyfus DH, Nagasawa M, Pratt JC, Kelleher CA, Gelfand EW. Inactivation of NF-KB by EBV BZLF-1 encoded ZEBRA protein in human T-cells. J Immunol. 1999;163:6261.
55. Fumari FB, Zacny V, Quinlivan EB, Kenney S, Pagano JS. RAZ, an Epstein-Barr virus transdominant repressor that modulates the viral reactivation mechanism. J Virol. 1994;68:1827.
56. Selivanova Q, Iotsova V, Okan I, et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med. 1997;3:632.
57. Gu W, Shi XL, Roeder RG. Synergistte activation of transcription by CBP and p53. Nature. 1997; 387:819.
58. Lill NL, Grossman SR, Ginsberg D, Decaprio J, Livingston DM. Binding and modulation of p53 by p300/CBP coactivators. Nature. 1997;387:823.
59. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, Kelly K. Recruitment of p300/CBP in p53-dependent signal pathways. Cell. 1997;89:1175.
60. Flamand L, Menezes J. Cyclic AMP-responsive element-dependent activation of Epstein-Barr virus Zebra promoter by human herpes virus 6. J Virol. 1996;70:1784.
61. Coffey AJ, Brooksbank RA, Brandau O, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet. 1999;20:129.